Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer
Abstract Background Hu-rhEGF-rP64k/Mont is a biotechnology product for the treatment of advanced non-small cell lung cancer (NSCLC). The vaccine induces a neutralizing antibody-mediated immune response, against the normal circulating self-protein antigen epidermal growth factor (EGF), which prevents...
Main Authors: | Puyuan Xing, Hongyu Wang, Sheng Yang, Xiaohong Han, Yan Sun, Yuankai Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | BMC Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12865-018-0249-9 |
Similar Items
-
Enhancement of Skin Wound Healing by rhEGF-Loaded Carboxymethyl Chitosan Nanoparticles
by: Pei Zhang, et al.
Published: (2020-07-01) -
rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects
by: Ji Min Kim, et al.
Published: (2020-10-01) -
Immuno-modulatory effect of local rhEGF treatment during tissue repair in diabetic ulcers
by: Natalio García-Honduvilla, et al.
Published: (2018-04-01) -
Potential protective effects of rhEGF against ultraviolet A irradiation-induced damages on human fibroblasts
by: Kim JM, et al.
Published: (2018-10-01) -
Effect of rhEGF eye drops on xerophthalmia after cataract surgery and its influence on tear film stability
by: Yang Hu, et al.
Published: (2019-08-01)